SCHEMBL16606151

SCHEMBL16606151

CC(C)(C)OC(=O)n1cc(I)c2nccc(C#N)c21

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.37
ELANE P08246 5/20 0.36
RET P07949 8/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22001362 0.84 ELANE (0.36) ELANE
SCHEMBL16593256 0.83 L3MBTL1 (0.34) GPR119
SCHEMBL16593246 0.82 ELANE (0.39) ELANE
SCHEMBL16606149 0.81 POLB (0.37) GPR119RET
SCHEMBL16606153 0.81 CFTR (0.37) GPR119
SCHEMBL10072162 0.75 GPR119 (0.35) GPR119ELANE
SCHEMBL16593587 0.75 L3MBTL1 (0.43) GPR119ELANE
SCHEMBL24096875 0.74 AR (0.34) GPR119ELANERET
SCHEMBL16593515 0.74 CHRM1 (0.47) GPR119RET
SCHEMBL16609850 0.73 GPR119 (0.37) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3489237-A1 4-AZAINDOLE DERIVATIVES Eisai R&D Management Co., Ltd. (JP) 2019-05-29 EP disclosed
US-20180208593-A1 4-Azaindole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-07-26 US disclosed
US-20180208593-A1 4-Azaindole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-07-26 US disclosed
US-9926312-B2 4-azaindole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-03-27 US disclosed
US-9926312-B2 4-azaindole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-03-27 US disclosed
US-20160244445-A1 4-Azaindole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-08-25 US disclosed
US-20160244445-A1 4-Azaindole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-08-25 US disclosed
US-20150094328-A1 4-Azaindole Derivatives EISAI R&D MAN CO LTD (JP) 2015-04-02 US disclosed
US-20150094328-A1 4-Azaindole Derivatives EISAI R&D MAN CO LTD (JP) 2015-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244445-A1 4-Azaindole Derivatives CHRM1, CHRM4, CHRM2 GPR119 109/4885ELANE 4283/4885RET 2033/4885
US-20180208593-A1 4-Azaindole Derivatives CHRM1, CHRM4, CHRM2 GPR119 109/4885ELANE 4283/4885RET 2033/4885
US-20150094328-A1 4-Azaindole Derivatives CHRM1, CHRM4, CHRM2 GPR119 109/4885ELANE 4283/4885RET 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.